On January 6, the board director, board secretary, and financial head of Furlia, Deng Baijiao, sat down for an interview with reporters from China Securities JournalDuring the conversation, she elaborated on the company's strong research and development (R&D) and innovation capabilities, stressing its commitment to the "Double Improvement of Quality and Returns" initiativeThis approach not only aims to provide better returns for investors but also to enhance the overall value of the company.

Since its inception, Furlia has focused passionately on the R&D, production, and sale of specialized skin care products, establishing itself as a leading enterprise in the realm of medical dressingsThe company boasts a rich assortment of products that vary in types and forms, with offerings ranging from medical device dressings to functional skin care itemsThese products are comprehensive in efficacy and adeptly cater to the diverse needs of the market and its clienteleFurlia has strategically developed a multidimensional product system that primarily features Class II medical device products aimed at treating mild to moderate acne, which aids in wound healing and skin repair, complemented by various functional skin care products based on in-depth research into sodium hyaluronate and collagen.

Moreover, Furlia is actively expanding into the Class III medical device sector, continuously broadening its product line to solidify its leading position in the professional skin care market.

The establishment of a Dual-R&D hub accelerates innovation and diversification.

In August of last year, Furlia inaugurated its Shanghai R&D center, which primarily aims to spearhead cosmetic product development while connecting with cutting-edge industry technologies to enrich its product lineupThis development marks the initiation of a collaborative R&D model that synergizes efforts between the Shanghai center and the Harbin R&D center, significantly enhancing the company’s research and innovation capabilities.

The Shanghai R&D center retains the essence of the brand, diving deep into raw material development and technology application

Advertisements

On the raw material front, it actively engages with new materials and technologies at the forefront of the industry, focusing extensively on plant extracts and human-origin componentsMeanwhile, on the technology application and formulation side, it promotes the translation of unique high-quality ingredients into well-crafted formulations and effective products, accelerating project initiation and research paceThe Harbin R&D center, uniquely positioned in Northeast China, leverages the region’s abundant natural resources and scientific talent to advance R&D efforts in medical device productsThe cooperative synergy between these two centers fully taps into the advantages of their geographical diversity.

In recent years, Furlia has consistently ramped up its R&D efforts, enhancing its research team and increasing R&D investmentMoreover, the company has forged partnerships with several higher education institutions and research institutes, collaborating with Northeast Forestry University, Harbin Institute of Technology (Shenzhen), Jiangnan University, Sichuan University, and Kunming Institute of Botany of the Chinese Academy of SciencesThrough these industry-academia-research collaboration initiatives, Furlia has made remarkable strides in research on supramolecular materials, novel plant extracts, and the upgrading of product processes and formulations, which has fostered closer research partnerships and facilitated the real-world application of research findings.

Through multifaceted R&D efforts, Furlia continues to make inroads in the II and III class medical devices and cosmetics sectors, enriching its product line while bolstering its technological barriers and core competitiveness.

A robust market growth trajectory allows for sustained investor returns.

The unwavering commitment to a strong R&D framework, a comprehensive product array, and an optimal product structure have all significantly underpinned Furlia's steady and sustainable growth

Advertisements

In recent years, the company has demonstrated a resilient revenue scaling, achieving a revenue of 1.466 billion yuan in the first three quarters of 2024, reflecting a 9.47% year-on-year growth and a steady uptick in market share.

"The market scale for functional skin care products and medical device dressings remains on a trajectory of continued expansion, providing robust foundational support for the company's market enlargement," stated Deng Baijiao. "We will persist in fostering cutting-edge technological competitiveness, driving industry-leading innovation with our results, and strive to enhance the company's overall competitiveness and market shareOur aim is to provide even more remarkable performance that benefits our investors, fostering a harmonious relationship with them and sharing the high-quality operational growth results of our company."

Furlia places high importance on shareholder returns, emphasizing the enhancement of its investor return potential and overall valueThe company aims to enhance investor satisfaction and showcases practical actions that set a demonstration effectListing on August 1, 2023, Furlia conducted its first post-listing dividend distribution in May 2024, rewarding all shareholders with a cash dividend of 10 yuan (gross) for every 10 shares, totaling 400 million yuan in cash dividends, representing 53.39% of the company's net profit attributable to shareholders for the year 2023.

Recently, Furlia announced a plan to distribute another round of dividends before the 2025 Lunar New Year, proposing a cash dividend of 5 yuan (gross) for every 10 shares, totaling 200 million yuan in cash dividendsFurthermore, Furlia actively engages in investor communication activities to aid investors in acquiring a deeper, more comprehensive understanding of the company, securing their right to information, and boosting their recognition of Furlia’s value propositionAt the same time, the firm enhances its information disclosure level, providing useful data for informed investor decision-making and continually elevating its influence and investment value within the professional skin care sector.

Over years of development, Furlia has managed to carve out a notable competitive edge across various facets, including products, channels, marketing, and operations, thereby continuing to lead in the realm of patch-based professional skin care products. "In an environment where the skin care market is flourishing, our company remains attuned to market fluctuations and keeps a close eye on evolving product technology trends as well as changing consumer demands

Advertisements

Advertisements

Advertisements